Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RESMED INC Director's Dealing 2022

Nov 17, 2022

30071_dirs_2022-11-16_6ebe7bda-f3c5-419a-8581-8580ca3f29e7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2022-11-15

Reporting Person: BLAISE LUCILE (President, Sleep & RC Business)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-11-15 ResMed Common Stock M 516 $225.18 Acquired 7504 Direct
2022-11-15 ResMed Common Stock S 169 $225.18 Disposed 7335 Direct

Footnotes

F1: The transaction was conducted under a Rule 10b5-1 plan.

F2: Includes 72.515 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan.